Review Article| Volume 50, ISSUE 1, P145-150, February 2023

The Evolving Landscape of Viral, Immune, and Molecular Biomarkers in Penile Cancer


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.


      Subscribe to Urologic Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Douglawi A.
        • Masterson T.A.
        Updates on the epidemiology and risk factors for penile cancer.
        Transl Androl Urol. 2017; 6: 785-790
        • Hernandez B.Y.
        • Barnholtz-Sloan J.
        • German R.R.
        • et al.
        Burden of invasive squamous cell carcinoma of the penis in the United States, 1998-2003.
        Cancer. 2008; 113: 2883-2891
        • Pow-Sang M.R.
        • Ferreira U.
        • Pow-Sang J.M.
        • et al.
        Epidemiology and natural history of penile cancer.
        Urology. 2010; 76: S2-S6
        • Leto M.
        • Santos Junior G.F.
        • Porro A.M.
        • et al.
        Human papillomavirus infection: etiopathogenesis, molecular biology and clinical manifestations.
        An Bras Dermatol. 2011; 86: 306-317
        • Spiess P.E.
        • Dhillon J.
        • Baumgarten A.S.
        • et al.
        Pathophysiological basis of human papillomavirus in penile cancer: Key to prevention and delivery of more effective therapies.
        CA Cancer J Clin. 2016; 66: 481-495
        • Stratton K.L.
        • Culkin D.J.
        A contemporary review of HPV and penile cancer.
        Oncology (Williston Park). 2016; 30: 245-249
        • Olesen T.B.
        • Sand F.L.
        • Rasmussen C.L.
        • et al.
        Prevalence of human papillomavirus DNA and p16(INK4a) in penile cancer and penile intraepithelial neoplasia: a systematic review and meta-analysis.
        Lancet Oncol. 2019; 20: 145-158
        • Weaver B.A.
        • Feng Q.
        • Holmes K.K.
        • et al.
        Evaluation of genital sites and sampling techniques for detection of human papillomavirus DNA in men.
        J Infect Dis. 2004; 189: 677-685
        • Chipollini J.
        • Chaing S.
        • Azizi M.
        • et al.
        Advances in understanding of penile carcinogenesis: the search for actionable targets.
        Int J Mol Sci. 2017; 18
        • Agarwal G.
        • Gupta S.
        • Spiess P.E.
        Novel targeted therapies for the treatment of penile cancer.
        Expert Opin Drug Discov. 2014; 9: 959-968
        • Scheffner M.
        • Werness B.A.
        • Huibregtse J.M.
        • et al.
        The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53.
        Cell. 1990; 63: 1129-1136
        • Ferreux E.
        • Lont A.P.
        • Horenblas S.
        • et al.
        Evidence for at least three alternative mechanisms targeting the p16INK4A/cyclin D/Rb pathway in penile carcinoma, one of which is mediated by high-risk human papillomavirus.
        J Pathol. 2003; 201: 109-118
        • Lopes A.
        • Bezerra A.L.
        • Pinto C.A.
        • et al.
        p53 as a new prognostic factor for lymph node metastasis in penile carcinoma: analysis of 82 patients treated with amputation and bilateral lymphadenectomy.
        J Urol. 2002; 168: 81-86
        • Djajadiningrat R.S.
        • Jordanova E.S.
        • Kroon B.K.
        • et al.
        Human papillomavirus prevalence in invasive penile cancer and association with clinical outcome.
        J Urol. 2015; 193: 526-531
        • Lont A.P.
        • Kroon B.K.
        • Horenblas S.
        • et al.
        Presence of high-risk human papillomavirus DNA in penile carcinoma predicts favorable outcome in survival.
        Int J Cancer. 2006; 119: 1078-1081
        • Bezerra A.L.
        • Lopes A.
        • Santiago G.H.
        • et al.
        Human papillomavirus as a prognostic factor in carcinoma of the penis: analysis of 82 patients treated with amputation and bilateral lymphadenectomy.
        Cancer. 2001; 91: 2315-2321
        • Fonseca A.G.
        • Soares F.A.
        • Burbano R.R.
        • et al.
        Human papilloma virus: prevalence, distribution and predictive value to lymphatic metastasis in penile carcinoma.
        Int Braz J Urol. 2013; 39: 542-550
        • Steinestel J.
        • Al Ghazal A.
        • Arndt A.
        • et al.
        The role of histologic subtype, p16(INK4a) expression, and presence of human papillomavirus DNA in penile squamous cell carcinoma.
        BMC Cancer. 2015; 15: 220
        • Trimble C.L.
        • Morrow M.P.
        • Kraynyak K.A.
        • et al.
        Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial.
        Lancet. 2015; 386: 2078-2088
        • Stevanovic S.
        • Draper L.M.
        • Langhan M.M.
        • et al.
        Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells.
        J Clin Oncol. 2015; 33: 1543-1550
        • Aydin A.M.
        • Hall M.
        • Bunch B.L.
        • et al.
        Expansion of tumor-infiltrating lymphocytes (TIL) from penile cancer patients.
        Int Immunopharmacol. 2021; 94: 107481
        • Stankiewicz E.
        • Prowse D.M.
        • Ng M.
        • et al.
        Alternative HER/PTEN/Akt pathway activation in HPV positive and negative penile carcinomas.
        PloS one. 2011; 6: e17517
        • Chaux A.
        • Munari E.
        • Katz B.
        • et al.
        The epidermal growth factor receptor is frequently overexpressed in penile squamous cell carcinomas: a tissue microarray and digital image analysis study of 112 cases.
        Hum Pathol. 2013; 44: 2690-2695
        • McDaniel A.S.
        • Hovelson D.H.
        • Cani A.K.
        • et al.
        Genomic profiling of penile squamous cell carcinoma reveals new opportunities for targeted therapy.
        Cancer Res. 2015; 75: 5219-5227
        • Di Lorenzo G.
        • Perdona S.
        • Buonerba C.
        • et al.
        Cytosolic phosphorylated EGFR is predictive of recurrence in early stage penile cancer patients: a retropective study.
        J Transl Med. 2013; 11: 161
        • Necchi A.
        • Lo Vullo S.
        • Perrone F.
        • et al.
        First-line therapy with dacomitinib, an orally available pan-HER tyrosine kinase inhibitor, for locally advanced or metastatic penile squamous cell carcinoma: results of an open-label, single-arm, single-centre, phase 2 study.
        BJU Int. 2018; 121: 348-356
        • Thomas A.
        • Reetz S.
        • Stenzel P.
        • et al.
        Assessment of PI3K/mTOR/AKT pathway elements to serve as biomarkers and therapeutic targets in penile cancer.
        Cancers (Basel). 2021; 13: 2323
        • Thomas A.
        • Slade K.S.
        • Blaheta R.A.
        • et al.
        Value of c-MET and associated signaling elements for predicting outcomes and targeted therapy in penile cancer.
        Cancers (Basel). 2022; 14: 1683
        • Chahoud J.
        • Gleber-Netto F.O.
        • McCormick B.Z.
        • et al.
        Whole-exome sequencing in penile squamous cell carcinoma uncovers novel prognostic categorization and drug targets similar to head and neck squamous cell carcinoma.
        Clin Cancer Res. 2021; 27: 2560-2570
        • Ottenhof S.R.
        • Djajadiningrat R.S.
        • Thygesen H.H.
        • et al.
        The prognostic value of immune factors in the tumor microenvironment of penile squamous cell carcinoma.
        Front Immunol. 2018; 9: 1253
        • Vassallo J.
        • Rodrigues A.F.
        • Campos A.H.
        • et al.
        Pathologic and imunohistochemical characterization of tumoral inflammatory cell infiltrate in invasive penile squamous cell carcinomas: Fox-P3 expression is an independent predictor of recurrence.
        Tumour Biol. 2015; 36: 2509-2516
        • Ahmed M.E.
        • Falasiri S.
        • Hajiran A.
        • et al.
        The immune microenvironment in penile cancer and rationale for immunotherapy.
        J Clin Med. 2020; 9: 3334
        • Azizi M.
        • Aydin A.M.
        • Hajiran A.
        • et al.
        Systematic review and meta-analysis-is there a benefit in using neoadjuvant systemic chemotherapy for locally advanced penile squamous cell carcinoma?.
        J Urol. 2020; 203: 1147-1155
        • Udager A.M.
        • Liu T.Y.
        • Skala S.L.
        • et al.
        Frequent PD-L1 expression in primary and metastatic penile squamous cell carcinoma: potential opportunities for immunotherapeutic approaches.
        Ann Oncol. 2016; 27: 1706-1712
        • Hahn A.W.
        • Chahoud J.
        • Campbell M.T.
        • et al.
        Pembrolizumab for advanced penile cancer: a case series from a phase II basket trial.
        Invest New Drugs. 2021; 39: 1405-1410
        • Chahoud J.
        • Skelton WPt
        • Spiess P.E.
        • et al.
        Case report: two cases of chemotherapy refractory metastatic penile squamous cell carcinoma with extreme durable response to pembrolizumab.
        Front Oncol. 2020; 10: 615298
        • Marabelle A.
        • Fakih M.
        • Lopez J.
        • et al.
        Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.
        Lancet Oncol. 2020; 21: 1353-1365